These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
856 related articles for article (PubMed ID: 10667461)
1. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Hein DW; Doll MA; Fretland AJ; Leff MA; Webb SJ; Xiao GH; Devanaboyina US; Nangju NA; Feng Y Cancer Epidemiol Biomarkers Prev; 2000 Jan; 9(1):29-42. PubMed ID: 10667461 [TBL] [Abstract][Full Text] [Related]
2. Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking. Okkels H; Sigsgaard T; Wolf H; Autrup H Cancer Epidemiol Biomarkers Prev; 1997 Apr; 6(4):225-31. PubMed ID: 9107426 [TBL] [Abstract][Full Text] [Related]
3. Metabolic activation of N-hydroxy-2-aminofluorene and N-hydroxy-2-acetylaminofluorene by monomorphic N-acetyltransferase (NAT1) and polymorphic N-acetyltransferase (NAT2) in colon cytosols of Syrian hamsters congenic at the NAT2 locus. Hein DW; Doll MA; Gray K; Rustan TD; Ferguson RJ Cancer Res; 1993 Feb; 53(3):509-14. PubMed ID: 8425184 [TBL] [Abstract][Full Text] [Related]
4. Effect of NAT1 and NAT2 genetic polymorphisms on colorectal cancer risk associated with exposure to tobacco smoke and meat consumption. Lilla C; Verla-Tebit E; Risch A; Jäger B; Hoffmeister M; Brenner H; Chang-Claude J Cancer Epidemiol Biomarkers Prev; 2006 Jan; 15(1):99-107. PubMed ID: 16434594 [TBL] [Abstract][Full Text] [Related]
5. Cloning, sequencing, and recombinant expression of NAT1, NAT2, and NAT3 derived from the C3H/HeJ (rapid) and A/HeJ (slow) acetylator inbred mouse: functional characterization of the activation and deactivation of aromatic amine carcinogens. Fretland AJ; Doll MA; Gray K; Feng Y; Hein DW Toxicol Appl Pharmacol; 1997 Feb; 142(2):360-6. PubMed ID: 9070359 [TBL] [Abstract][Full Text] [Related]
6. Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. Hein DW Mutat Res; 2002 Sep; 506-507():65-77. PubMed ID: 12351146 [TBL] [Abstract][Full Text] [Related]
7. Polymorphic NATs and cancer predisposition. Hirvonen A IARC Sci Publ; 1999; (148):251-70. PubMed ID: 10493262 [TBL] [Abstract][Full Text] [Related]
8. Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of liver isozymes and expressed products of two cloned genes. Grant DM; Blum M; Beer M; Meyer UA Mol Pharmacol; 1991 Feb; 39(2):184-91. PubMed ID: 1996083 [TBL] [Abstract][Full Text] [Related]
9. Association of NAT1 and NAT2 polymorphisms to urinary bladder cancer: significantly reduced risk in subjects with NAT1*10. Cascorbi I; Roots I; Brockmöller J Cancer Res; 2001 Jul; 61(13):5051-6. PubMed ID: 11431340 [TBL] [Abstract][Full Text] [Related]
10. Polyadenylation polymorphism in the acetyltransferase 1 gene (NAT1) increases risk of colorectal cancer. Bell DA; Stephens EA; Castranio T; Umbach DM; Watson M; Deakin M; Elder J; Hendrickse C; Duncan H; Strange RC Cancer Res; 1995 Aug; 55(16):3537-42. PubMed ID: 7627961 [TBL] [Abstract][Full Text] [Related]
11. Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases. Hein DW; Doll MA; Rustan TD; Gray K; Feng Y; Ferguson RJ; Grant DM Carcinogenesis; 1993 Aug; 14(8):1633-8. PubMed ID: 8353847 [TBL] [Abstract][Full Text] [Related]
12. N-acetyltransferase (NAT2) polymorphism and breast cancer susceptibility: a lack of association in a case-control study of Turkish population. Kocabaş NA; Sardaş S; Cholerton S; Daly AK; Karakaya AE Int J Toxicol; 2004; 23(1):25-31. PubMed ID: 15162844 [TBL] [Abstract][Full Text] [Related]
13. 4-Aminobiphenyl downregulation of NAT2 acetylator genotype-dependent N- and O-acetylation of aromatic and heterocyclic amine carcinogens in primary mammary epithelial cell cultures from rapid and slow acetylator rats. Jefferson FA; Xiao GH; Hein DW Toxicol Sci; 2009 Jan; 107(1):293-7. PubMed ID: 18842621 [TBL] [Abstract][Full Text] [Related]
14. Genetic polymorphisms of N-acetyltransferase 1 and 2 and risk of cigarette smoking-related bladder cancer. Hsieh FI; Pu YS; Chern HD; Hsu LI; Chiou HY; Chen CJ Br J Cancer; 1999 Oct; 81(3):537-41. PubMed ID: 10507782 [TBL] [Abstract][Full Text] [Related]
15. Sequence variants of NAT1 and NAT2 and other xenometabolic genes and risk of lung and aerodigestive tract cancers in Central Europe. McKay JD; Hashibe M; Hung RJ; Wakefield J; Gaborieau V; Szeszenia-Dabrowska N; Zaridze D; Lissowska J; Rudnai P; Fabianova E; Mates D; Foretova L; Janout V; Bencko V; Chabrier A; Hall J; Boffetta P; Canzian F; Brennan P Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):141-7. PubMed ID: 18199719 [TBL] [Abstract][Full Text] [Related]
16. Role of aromatic amine acetyltransferases, NAT1 and NAT2, in carcinogen-DNA adduct formation in the human urinary bladder. Badawi AF; Hirvonen A; Bell DA; Lang NP; Kadlubar FF Cancer Res; 1995 Nov; 55(22):5230-7. PubMed ID: 7585581 [TBL] [Abstract][Full Text] [Related]
17. Para-phenylenediamine and allergic sensitization: risk modification by N-acetyltransferase 1 and 2 genotypes. Blömeke B; Brans R; Coenraads PJ; Dickel H; Bruckner T; Hein DW; Heesen M; Merk HF; Kawakubo Y Br J Dermatol; 2009 Nov; 161(5):1130-5. PubMed ID: 19663877 [TBL] [Abstract][Full Text] [Related]
18. Polymorphism in the N-acetyltransferase 1 (NAT1) polyadenylation signal: association of NAT1*10 allele with higher N-acetylation activity in bladder and colon tissue. Bell DA; Badawi AF; Lang NP; Ilett KF; Kadlubar FF; Hirvonen A Cancer Res; 1995 Nov; 55(22):5226-9. PubMed ID: 7585580 [TBL] [Abstract][Full Text] [Related]
19. Higher frequency of aberrant crypt foci in rapid than slow acetylator inbred rats administered the colon carcinogen 3,2'-dimethyl-4-aminobiphenyl. Feng Y; Fretland AJ; Rustan TD; Jiang W; Becker WK; Hein DW Toxicol Appl Pharmacol; 1997 Nov; 147(1):56-62. PubMed ID: 9356307 [TBL] [Abstract][Full Text] [Related]
20. Polymorphisms of glutathione-S-transferase and arylamine N-acetyltransferase enzymes and susceptibility to colorectal cancer. Kiss I; Németh A; Bogner B; Pajkos G; Orsós Z; Sándor J; Csejtey A; Faluhelyi Z; Rodler I; Ember I Anticancer Res; 2004; 24(6):3965-70. PubMed ID: 15736440 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]